Ensysce Biosciences Inc Aktie News

~ New U.S. Patent Extends Protection Through 2042 ~ ~ Patent Allowance Secures Highest Level of Intellectual Property Protection for MPAR® ~ SAN DIEGO, CA / ACCESS Newswire / December 2, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize ...

~ FDA Response Streamlines Path to Commercial Production of PF614~ SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize abuse and overdose risk, today announced that the Food and Drug Administr...

~Funding supports Phase 3 clinical development of PF614 and continued innovation in abuse- and overdose-resistant analgesics~ SAN DIEGO, CA / ACCESS Newswire / November 17, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC)("Ensysce" or the "Company"), pioneering novel solutions for severe pain with built-in abuse and overdose protection, today announced the closing of a $4 million convertible pref...

~ Third Quarter Highlighted by Initiation of Phase 3 Study of PF614, Underscoring Progress Toward Market Readiness and Commitment to Novel Opioid Solutions ~ ~ Further Program Advancement Supported by Preferred Stock Financing ~ SAN DIEGO, CA / ACCESS Newswire / November 14, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pion...

~ Pain Management, RE-Invented: Ushering in a New Era for Analgesia ~ SAN DIEGO, CA / ACCESS Newswire / October 10, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain therapeutics designed to minimize abuse and overdose risk, has released video highlights from its widely attended symposium at PAINW...

~ Experts Spotlight TAAP™ and MPAR® as Next-Generation Solutions for Severe Pain ~ SAN DIEGO, CA / ACCESS Newswire / September 4, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today shared key takeaways from its standing-room-...

~ The Summit is the Premier Industry Event for Defining How New Product Planning Teams and Related Functions Make Informed, Value-Based, Data-Driven Decisions ~ ~ Ensysce Biopharma Leader to Deliver Opening Remarks and Present Case Study on Launching Successful Brands ~ SAN DIEGO, CA / ACCESS Newswire / August 19, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company pioneeri...

New York, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC). The update note includes information on Ensysce Biosciences' business updates, management commentary, financial results, valuation, and risks.